An interventional study of L-Phenylalanine in Autosomal Recessive Disorder (Genetic Carriers of PKU), sponsored by University of Guelph. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by University of Guelph · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Genetic Diseases, Inborn with a site in Canada — 20 open to participants now, 27 under way, 7 of them phase 3. Genetic Diseases, Inborn · Canada.
Among the 77 studies in Genetic Diseases, Inborn with a site in Canada, this one is the 60th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2023, is one of 8 with no phase, and was the 57th registered.
585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.
Browse Genetic Diseases, Inborn studies →20 of the 77 studies in Genetic Diseases, Inborn with a site in Canada are open now. Recruiting first, the newest first:
Biossil Inc. · Sites in Canada
Ages 16–50
Avidity Biosciences, Inc. · Sites in Canada, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
BioMarin Pharmaceutical · Sites in Canada, United States, Australia and 6 more countries
Ages 2–17
CHU de Quebec-Universite Laval · Sites in Canada
Ages 7+
PepGen Inc · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 33 · Phase 3 25
First in 2006; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 41 across 306 interventional studies indexed under Genetic Diseases, Inborn.
Median enrollment 60 across the 63 interventional studies, 74 across the 14 observational. Of the 49 that completed or were terminated, 27 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 77 have an industry lead sponsor. The 10 most frequent:
University of Guelph is the lead sponsor of 71 studies on the registry; 6 are open to participants now.
University of Guelph has 2 studies filed under Genetic Diseases, Inborn — fewer than ten, so there is no comparison to draw.
6 of the studies in Genetic Diseases, Inborn with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT05095727ModernaTX, Inc.A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | 2026-11-30 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07073378University of CalgaryBCI@Home: Brain Computer Interface Solutions to Enable Youth Living With Severe Disabilities | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 77 studies in Genetic Diseases, Inborn with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical intervention pilot/feasibility study of PKU carriers (cases) and non-carriers (controls). Upon completing the informed consent process, participants will complete baseline measures of chronic mental health prior to the intervention (PHQ-9, GAD-7, BIS-Brief). Participants will attend the Human Nutraceutical Research Unit (HNRU) at the University of Guelph, fasted, and first undergo baseline measures of cognition and acute mental health (mood) and provide samples or saliva, urine and dried blood spots to evaluate phenylalanine (Phe), tyrosine (Tyr) and their metabolites (PAH pathway functioning). Participants will also complete a brief questionnaire which will include age, sex, ethnicity, income, weight and height (measured using a stadiometer and calibrated weigh scale), and confirmation that participants arrived to the lab fasted (i.e. have only had water to drink and no other foods/beverages prior to analyses). Blood pressure will also be measured at baseline. Following baseline tests, participants will consume a pure L-Phe supplement dosed at 100 mg/kg mixed into 250 mL water with 1 tsp white sugar. Blood pressure will be repeated at 1-hour post-L-Phe consumption. Two-hours postprandial, participants will repeat the cognitive tests and acute mental health (mood) assessment, blood pressure measurement and provide follow-up saliva, urine and dried blood spot samples. Participants will also be asked to report any side effects they experienced with the L-Phe consumption.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: L-Phenylalanine
100 mg/kg
Stop Signal Reaction Time (Response Inhibition)
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Working Memory
N-Back Test Outcome
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Stop Signal Delay
Stop Signal Task Outcome
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Individual Coefficient of Variance (Variability in Reaction Times)
Stop Signal Task Outcome
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Phenylalanine Levels
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Tyrosine Levels
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Phenylalanine Metabolites: e.g.phenylethylamine, tyramine, phenylpyruvate, others
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Tyrosine Metabolites: e.g. L-DOPA, dopamine, norepinephrine, epinephrine, p-hydroxyphenylpyruvate, homogentisic acid, fumarate, others
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Mood
Profile of Mood States (POMS) Outcome
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Blood Pressure
Systolic and Diastolic
Time frame: Change from baseline to 1-hour and 2-hours post L-Phe supplementation
Chronic Anxiety
GAD-7 Outcome
Time frame: Baseline
Chronic Depression
PHQ-9 Outcome
Time frame: Baseline
Impulsivity
BIS-Brief Outcome
Time frame: Baseline
Trial-by-trial analysis
To be conducted if there are significant findings from the four main stop signal task outcomes
Time frame: Change from baseline to 2-hours post L-Phe supplementation
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Dec 2023, 5 months.
Of 64 non-industry interventional studies with no phase under Genetic Diseases, Inborn, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's 5 months is below that.
Counting every sponsor, half of 66 studies reached it within 41 months; a quarter within 22 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenylalanine
University of Guelph